Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 166 от 222

Набира участници Фаза 3

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Glioma Astrocytoma, Grade IV IDH1-mutant Glioma Astrocytoma, IDH-Mutant, Grade 3 +4

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled. The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.

Начало: 05.06.2023 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, China, United States Nuvation Bio Inc. NCT05303519

Набира участници

Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes

Insulin Resistance Depression Depressive Disorder Mood Disorders +4

The investigators are doing this study to learn more about how to prevent type 2 diabetes in teenage girls. The purpose of this study is to find out if taking part in a cognitive-behavioral therapy group, exercise training group, or a combination of cognitive-behavioral therapy and exercise training groups, decreases stress, improves mood, increases physical activity and physical fitness, and decreases insulin resistance among teenagers at risk for diabetes.

Начало: 02.06.2023 Край: 31.03.2029 Възраст: 12–17 г.

United States Colorado State University NCT05543083

Набира участници Фаза 2

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

Kidney Transplantation in Highly Sensitized Patients

The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD). The main questions it aims to answer are: * Does imlifidase treatment result in crossmatch conversion that enables transplantation? * How is the function of the transplanted kidney? The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.

Начало: 02.06.2023 Край: 31.08.2031 Възраст: 1–17 г.

Finland, France, Spain +2 Hansa Biopharma AB NCT05753930

Набира участници

Intermittent Hypoxic Training (IHT) Versus Hyperbaric Oxygen Therapy (HBOT) for Aerobic Performance

Healthy Active Athletes

Comparing the effect of HBOT and IHT on aerobic performance of athletes.

Начало: 01.06.2023 Край: 31.12.2027 Възраст: 18–45 г.

Israel Assaf-Harofeh Medical Center NCT05447416

Набира участници

Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome

Covid19 Neurocognitive Dysfunction

Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome

Начало: 01.06.2023 Край: 31.12.2027 Възраст: от 18 г.

Israel Assaf-Harofeh Medical Center NCT04647656

Набира участници

Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis

Periodontitis Periodontal Diseases Periodontal Inflammation Gingival Diseases +1

The goal of this observational study is to examine JAK1/2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is: Is the JAK1/2 pathway overactivated in periodontitis compared to health? Participants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1/2 pathway. All participants wil receive diagnosis and treatment of the gingival condition.

Начало: 01.06.2023 Край: 31.03.2027 Възраст: от 18 г.

Chile University of Chile NCT07536204

Набира участници

Treatments in Women Veterans With Insomnia and PTSD

Insomnia PTSD Women Veterans

This pilot trial will compare trauma-informed Cognitive Behavioral Therapy for Insomnia (CBT-I) to a psychoeducational intervention in women Veterans with comorbid insomnia and posttraumatic stress disorder (PTSD). The CBT-I intervention includes trauma-informed adaptations to an insomnia treatment and the psychoeducational intervention is modeled after usual care in a VA Women's Mental Health Clinic. The study objectives are to: 1) Iteratively refine the structure and materials of trauma-informed CBT-I in preparation for a pilot trial, 2) Pilot test the effects of trauma-informed CBT-I on PTSD treatment readiness and engagement in a sample of women Veterans, and 3) Examine potential mechanisms underlying variations in PTSD treatment readiness and engagement over time among women Veterans. Women Veterans with insomnia and comorbid PTSD who receive care at Sepulveda and West Los Angeles facilities will be recruited for the study. Those who pass an initial eligibility screen will be enrolled and written informed consent will be obtained. A baseline assessment will be completed that includes measures of PTSD treatment readiness, perceived barriers to PTSD treatment, and sleep and mental health symptoms. Then Veterans who meet all eligibility criteria will be randomly assigned to trauma-informed CBT-I (n=25) or the psychoeducational intervention (n=25). Both treatments will be provided in 5 one-on-one sessions by a trained instructor who is supervised by a behavioral sleep medicine specialist. All randomized participants (n=50) will have 2 follow-up assessments (post-treatment and 3-months). The follow-up assessments will collect information on PTSD treatment readiness, perceived barriers to PTSD treatment, and sleep and mental health symptoms. Chart reviews will be conducted 6-months post-treatment to assess number of PTSD treatment appointments attended (treatment engagement measure). Qualitative interviews will be conducted to identify mechanisms underlying PTSD treatment engagement.

Начало: 01.06.2023 Край: 31.12.2028 Възраст: от 18 г.

United States VA Office of Research and Development NCT05683132

Набира участници

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

Lynch Syndrome Lynch Syndrome I Lynch Syndrome II Lynch Syndrome I (Site-specific Colonic Cancer) +18

Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.

Начало: 01.06.2023 Край: 01.06.2034 Възраст: от 18 г.

Italy, United States San Raffaele University NCT06708429

Набира участници Фаза 4

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

Sepsis Ivabradine Hemodynamics Heart Rate Control

Sepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of adequate volume resuscitation to correct hypovolemia and vasopressor medication to correct hypotension. Recently, relevant studies have shown that sustained tachycardia in sepsis was also related to high mortality, and appropriate control of heart rate could improve prognosis. Ivabradine reduces heart rate directly without a negative inotropic effect through inhibition of the If ionic current，which is absent from the traditional rate control drug (beta-blockers). This is a prospective, multicenter, randomized, open label study designed to compare ivabradine with placebo on the difference of heart rate and haemodynamics in patients with sepsis.

Начало: 01.06.2023 Край: 31.05.2027 Възраст: от 18 г.

China Second Affiliated Hospital of Guangzhou Medical Univers NCT05882708

Набира участници Фаза 2/3

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure Left Ventricular Systolic Dysfunction

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

Начало: 31.05.2023 Край: 15.04.2032 Възраст: 29–17 г. Лечение

Belgium, Brazil, Canada +26 Merck Sharp & Dohme LLC NCT05714085

Набира участници Фаза 1/2

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Locally Advanced Solid Tumor

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Начало: 26.05.2023 Край: 01.09.2026 Възраст: от 18 г.

France, Spain, United States Tango Therapeutics, Inc. NCT05732831

Набира участници

Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome

Myofascial Pain Syndrome - Lower Back Myofascial Pain Syndrome - Neck Myofascial Pain Syndrome - Tension Headache

Sonodyn is an investigational device that within this clinical investigation is intended for use in patients suffering from low back pain, tension headache or neck pain, originating from therapy-resistant myofascial pain syndrome. Myofascial pain syndrome is a prevalent pain condition in the adult population and a common cause of pain and dysfunction in the musculoskeletal system. It is a trigger point-induced regional musculoskeletal pain disorder affecting one or more muscles or groups of muscles. Sonodyn is a handheld medical device that combines low-energy ultrasound, electrical and magnetic field stimulation for non-invasive transcutaneous treatment of chronic myofascial pain syndrome. Sonodyn is a battery-operated, rechargeable stimulation device to be placed over specific trigger points for associated pain patterns in the human body. It emits ultrasound, electrical and magnetic stimulation signals with a pre-defined set of parameters for each of the independently operated power sources. The study will follow a prospective, randomized, sham-controlled, double-blind parallel group design. It will be conducted as a multi-center investigation at 6 sites in Austria and Switzerland. Patients are randomized in a 2:1 ratio into Treatment and Control. * Active Sonodyn therapy (Treatment) * No therapy (Sham Control) Two types of Sonodyn devices will be used: a fully functional one for Therapy arm patients that can deliver stimulation, and a non-functional one for Control arm patients that cannot convey any energy signals to the device output. The devices will look fully identical. Randomization will be stratified by study site, pain diagnosis and sex of the patient. For each subject, after a screening phase of 1 week, patients will be treated for 3 weeks with a follow-up of additional 8 weeks, adding up to 12 weeks. During treatment patients will activate their device 3 times a day for 10 minutes each. During screening, treatment and follow-up period, all patients will twice per day report the average and maximum intensity of their pain Numeric Rating Scale (NRS). Patients will also enter the date, amount, and time of intake of rescue medication, if applicable. The primary objective of this study is to assess the impact on pain. Secondary objectives are to compare the performance between active therapy and sham, as well as to correlate changes in pain intensity with other pain related scales.

Начало: 25.05.2023 Край: 01.06.2027 Възраст: 18–99 г.

Austria, Switzerland Sobet AG NCT05851326

Набира участници

Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging

Lung Cancer

This trial will investigate the feasibility of the Markerless Tumour Tracking technology.

Начало: 24.05.2023 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia University of Sydney NCT04086082

Набира участници Фаза 1

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Malignant Glioma

This phase I trial finds out the possible benefits and/or side effects of radiosurgery before surgery (preoperative) in treating patients with high grade glioma. Radiosurgery uses special equipment to position the patient and precisely give a single large dose of radiation to the tumor. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pre-operative radiosurgery may improve the odds of brain tumor control and reduce treatment-related side effects.

Начало: 23.05.2023 Край: 15.09.2027 Възраст: от 18 г.

United States Mayo Clinic NCT05030298

Набира участници Фаза 1

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Solid Tumor, Adult Advanced Solid Tumor Advanced Renal Cell Carcinoma

This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.

Начало: 23.05.2023 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia Telix Pharmaceuticals (Innovations) Pty Limited NCT05868174

Набира участници Фаза 1/2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Cancer Colorectal Cancer Solid Tumor Locally Advanced Solid Tumor +11

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

Начало: 23.05.2023 Край: 31.08.2027 Възраст: от 18 г.

United States Parabilis Medicines, Inc. NCT05919264

Набира участници

Randomized Assessment of TcMS for VT Storm

Ventricular Tachycardia

Three-arm randomized clinical trial comparing two strategies of TcMS to sham stimulation in patients with VT storm. The hypothesis of the study is that TcMS will reduce the burden of VT in the 24 hours after randomization compared to sham stimulation and that TcMS with theta burst stimulation (TBS) will be more effective at reducing VT burden than low frequency TcMS.

Начало: 22.05.2023 Край: 01.10.2028 Възраст: от 18 г.

United States University of Pennsylvania NCT05599022

Набира участници

Brain Controlled Spinal Cord Stimulation in Participants With Cervical Spinal Cord Injury for Upper Limb Rehabilitation

Cervical Spinal Cord Injury Tetraplegia

Cervical spinal cord stimulation can elicit arm and hand movements through recruitment of proprioceptive neurons in the dorsal roots. In participants with cervical spinal cord injury, the spare roots bellow the lesion can be used to reactivate motor function. Decoding of motor intentions can be achieved through implantable electrocorticography (ECoG) devices. In this study, the investigators will use an investigational system using ECoG signal recording over the motor cortex to drive muscle specific electrical epidural spinal cord stimulation (EES). The investigators will assess the safety and preliminary efficacy of this system in 3 participants.

Начало: 22.05.2023 Край: 31.12.2026 Възраст: 18–75 г.

Switzerland Ecole Polytechnique Fédérale de Lausanne NCT05665998

Набира участници Фаза 2

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Ovarian Carcinosarcoma Uterine Carcinosarcoma

The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizumab.

Начало: 22.05.2023 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, United Kingdom Australia New Zealand Gynaecological Oncology Group NCT05619913

Набира участници Фаза 1/2

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Advanced Solid Malignancy

This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.

Начало: 21.05.2023 Край: 30.04.2028 Възраст: от 18 г. Лечение

Australia, France, Spain +1 Grey Wolf Therapeutics NCT06923761

1 … 164 165 166 167 168 … 222